Jazz Pharmaceuticals Announces Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Jazz Pharmaceuticals (JAZZ) PT Raised to $206 at BMO Capital
August 8, 2018 7:00 AM EDTBMO Capital raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $206.00 (from $201.00) while maintaining a Outperform rating.
Analsyt Gary Nachman commented, 'JAZZ reported a solid top and bottom line beat with 2Q revenue of $501mm vs. BMO/consensus $466mm/$470mm, and adj. EPS... More
Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 26c
August 7, 2018 4:43 PM EDTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $3.49, $0.26 better than the analyst estimate of $3.23. Revenue for the quarter came in at $500.48 million versus the consensus estimate of $469.62 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2018 EPS of $12.75-$13.25, versus the consensus of $13.09.... More
